We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients

By LabMedica International staff writers
Posted on 30 Sep 2019
A large genome-wide association study (GWAS) identified 16 genetic loci linked to the development of kidney disease by individuals with type I diabetes.

Although earlier studies have found that diabetic kidney disease has a heritable component, searches for the genetic determinants of this complication of diabetes have had limited success. More...


To identify genetic variants that predispose people to diabetic kidney disease, investigators at Harvard Medical School (Boston, MA, USA) and their colleagues performed genome-wide association analyses on samples from19,406 individuals of European descent with type I diabetes, with and without kidney disease.

Results revealed 16 genome-wide loci linked to significant risk of developing kidney disease. The variant with the strongest association was a common missense mutation (a point mutation in which a single nucleotide change results in a codon that codes for a different amino acid) in the collagen type IV alpha 3 chain (COL4A3) gene, which encodes a major structural component of the glomerular basement membrane (GBM).

Mutations in COL4A3 have been implicated in heritable kidney disorders, including the progressive inherited nephropathy Alport syndrome.

“This study represents a substantial advance in the genetics of diabetic kidney disease, where previous studies had yielded few robust associations,” said senior author Dr. Jose C. Florez, professor of medicine at Harvard Medical School. “The 16 diabetic kidney disease-associated regions provide novel insights into the pathogenesis of diabetic kidney disease, identifying potential biological targets for prevention and treatment.”

Related Links:
Harvard Medical School


New
Gold Member
Automatic Hematology Analyzer
CF9600
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The method that profiles DNA methylation in cell-free DNA from a single blood sample to detect disease signals system-wide (photo courtesy of Shutterstock)

cfDNA Methylation Assay Enables Multi-Disease Detection from Single Blood Sample

Early, accurate detection of cancer and organ disease remains limited by cost, reliance on targeted mutation assays, and uncertainty about the signal’s tissue of origin. Many liquid biopsy approaches require... Read more

Immunology

view channel
Image: Mycobacterium tuberculosis bacteria seen with a scanning electron microscope (Credit: CDC PHIL)

Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection

Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more

Pathology

view channel
Image: Spatial characterization of immune–tumor interactions and treatment response across SCLC and extended phenotype models (Cristian Barrera et al, npj Precision Oncology (2026). DOI: 10.1038/s41698-025-01225-9)

AI Pathology Tool Predicts Chemotherapy Response in Small Cell Lung Cancer

Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.